<DOC>
	<DOC>NCT01111240</DOC>
	<brief_summary>This study is a documentation of effectiveness and safety of Humira in patients with psoriatic arthritis.</brief_summary>
	<brief_title>Efficacy and Safety of HumiraÂ® in Patients With Psoriatic Arthritis in Normal Medical Practice</brief_title>
	<detailed_description>Psoriatic Arthritis participants receiving adalimumab are evaluated in a prospective, non-interventional study (NIS) for 2 years. Patients receive adalimumab 40 mg every other week (eow), per its label. Efficacy and safety parameters are measured routinely at baseline and after 3, 6, 9, 12, 18 and 24 months.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion: 18 years of age or older (younger patients may be enrolled at the discretion of physician) Diagnosis of Psoriatic Arthritis (or any indication at the discretion of physician) and initiating adalimumab therapy Signed/dated Informed Consent Exclusion:</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Humira</keyword>
	<keyword>Long-term safety and effectiveness</keyword>
	<keyword>Psoriatic Arthritis</keyword>
</DOC>